Clinical trials: Treatment Resistant Schizophrenia
Clozapine Resistant Schizophrenia
Maintenance Electroconvulsive Therapy (ECT) Versus Aripiprazole in Clozapine-resistant Schizophrenia
The pharmacological treatment options in schizophrenia developing resistance to clozapine are limited. Few studies have found ECT as beneficial in TRS, including CRS.
- Trial name
- NCT06501339
- Testing
- maintenance ECT, Aripiprazole tablet
- Volunteers
- 40 people
- Sponsor
- All India Institute of Medical Sciences, Bhubaneswar
Schizophrenia
Lamictal TM, Haloperidol Decanoate in Schizophrenia
The purpose of this study is to determine the effect of lamotrigine augmentation of Haloperidol decanoate in the treatment of Resistant Schizophrenia predominantly by verbal resistant hallucinosis: A randomized, double-blind…
- Trial name
- CMCOBaku (NCT00947375)
- Testing
- Lamictal TM, Haloperidol Decanoate
- Where
- Azerbaijan
- Volunteers
- 335 people
- Sponsor
- Central Mental Clinic for Outpatients of Baku City
Schizo Affective Disorder, Schizophrenia
L-arginine Study for Persistent Symptoms of Schizophrenia
The purpose of this research is to see if daily combination treatment of L-arginine and Kuvan changes brain chemistry in people experiencing schizophrenia as measured by MRS brain scans.
- Trial name
- NCT04054973
- Testing
- L-arginine, Sapropterin Dihydrochloride
- Where
- United States
- Sponsor
- University of Massachusetts, Worcester
Treatment Resistant Schizophrenia
Comparison of Maintenance ECT Versus Clozapine in Treatment-resistant Schizophrenia
The proposed study will be conducted to compare the efficacy of maintenance ECT (M-ECT) vs Clozapine in treatment resistant schizophrenia (TRS) in terms of change in psychopathology measures and cerebral hemodynamics.
- Trial name
- NCT03807882
- Testing
- Bilateral M-ECT, Clozapine
- Where
- India
- Volunteers
- 60 people
- Sponsor
- All India Institute of Medical Sciences, Bhubaneswar
Schizophrenia
β-Cell Function in Schizophrenic Subjects on Atypical Antipsychotic drugS
The purpose of this study is to determine whether atypical antipsychotic drugs (commonly prescribed for treating schizophrenia) induce changes in anthropometry and metabolism, including alteration in insulin sensitivity and/or…
- Trial name
- SANAT (NCT00528359)
- Testing
- quetiapine or olanzapine or risperidone or aripiprazole
- Where
- Belgium
- Volunteers
- 36 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Schizophrenia
DAAOI-1 Treatment for Treatment-resistant Schizophrenia
Pharmacotherapy for schizophrenia has limitations such as residual positive and negative symptoms, cognitive deficits and intolerable side effects.
- Trial name
- NCT01390376
- Testing
- DAAOI-1
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- China Medical University Hospital
Schizophrenia, Schizoaffective Disorder
Efficacy and Safety Study of Escitalopram Augmentation in Treatment Resistant Schizophrenia
A primary hypothesis to be explored here is that, given its pharmacodynamic profile and hypothesized mechanisms associated with schizophrenia, escitalopram will, in comparison to placebo, be effective when added to risperidone or…
- Trial name
- NCT00231335
- Testing
- escitalopram
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Emory University
Schizophrenia Disorders, Treatment Resistant Hallucinations
Cognitive and Metacognitive Evaluation in VR-Based Avatar Therapy for Psychosis
This study aims to evaluate the relationship between cognitive, metacognitive and social cognition variables in patients with psychosis undergoing VR-based Avatar Therapy for the treatment of auditory hallucinations.
- Trial name
- Meta-VR-AVATAR (NCT07091344)
- Testing
- VR-Based Avatar Therapy with Cognitive and Metacognitive Assessments
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Fundació Sant Joan de Déu
Schizophrenia, Metabolic Syndrome
Optimizing and Individualizing the Pharmacological Treatment of First-episode Schizophrenic Patients
The study is performed in 20 different hospitals from 19 cities in China. Three sub-projects are included. About sub-project 1, we build a clinical database system and a biological sample bank for data and samples management…
- Trial name
- NCT03451734
- Testing
- antipsychotic medications, adjunctive group, metformin and lifestyle intervention
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Central South University
Schizophrenia, Schizo Affective Disorder
Acetazolamide for Treatment Resistant Schizophrenia
This is a double blind adjunctive randomized controlled trial for schizophrenia using acetazolamide.
- Trial name
- APTS (NCT04887792)
- Testing
- Acetazolamide
- Where
- 2 sites in United States, India
- Volunteers
- 60 people
- Sponsor
- Vishwajit Nimgaonkar, MD PhD
Schizophrenia, Serious Mental Illness
Cross-Sectional Iloperidone IVGTT
This study aims to utilize state of the art procedures such as the frequently sampled intravenous glucose tolerance test (FSIVGTT), Bergman's Minimal Model Analysis, lipoprotein analysis, and DEXA scans to demonstrate that a…
- Conditions
- Schizophrenia, Serious Mental Illness, Metabolic Syndrome, Insulin Resistance
- Trial name
- NCT01686815
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Massachusetts General Hospital
Schizophrenia, Schizophrenia and Related Disorders
Ketogenic Metabolic Therapy in Schizophrenia, Bipolar Disorder, Major Depressive Disorder: Deep Omic Profiling
The goal of this randomized clinical trial is to be adequately powered to evaluate the effect of ketogenic metabolic therapy on the quality of life in serious mental illness, schizophrenia, bipolar disorder, major depressive…
- Conditions
- Schizophrenia, Schizophrenia and Related Disorders, Bipolar Disorder, Bipolar and Related Disorders
- Trial name
- NCT06748950
- Testing
- LCHF Ketogenic Diet, Diet-as-Usual (DAU)
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Stanford University
Schizophrenia, Prediabetic State
Home-based Intervention With Semaglutide Treatment Of Neuroleptica-Related Prediabetes
To investigate whether the Glucagon Like Peptide 1 (GLP-1) Semaglutide (1.34 mg/ml) has preventive effect compared to placebo in the development of diabetes and Metabolic Syndrome in people with pre-diabetes, overweight and…
- Trial name
- HISTORI (NCT05193578)
- Testing
- Semaglutide, 1.34 mg/mL
- Where
- Denmark
- Volunteers
- 154 people
- Sponsor
- Jan Frystyk
Schizophrenia, Insulin Resistance
Effectiveness of Aripiprazole for Improving Side Effects of Clozapine in the Treatment of People With Schizophrenia
This study will evaluate the effects of combination treatment with aripiprazole and clozapine on insulin resistance, blood fat levels, and weight gain in people diagnosed with schizophrenia.
- Trial name
- NCT00345033
- Testing
- Aripiprazole
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Massachusetts General Hospital
Schizophrenia
Low and High Frequency Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Resistant Auditory Hallucination in Schizophrenia
Auditory Hallucinations (AH) are experienced by 50 to 70% of subjects with schizophrenia. Almost a quarter of patients are medication resistant to such symptoms.
- Trial name
- rTMS (NCT02175251)
- Testing
- high frequency (20Hz), low frequency (1Hz)
- Where
- France
- Volunteers
- 33 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Schizophrenia, Diabetes
Medication Reviews in Severe Mental Illness
This study aims to investigate the potential beneficial effects of a medication review by a clinical pharmacologist on patients with coexisting severe mental illness and diabetes.
- Conditions
- Schizophrenia, Diabetes, Metabolic Syndrome, Severe Mental Disorder
- Trial name
- NCT05243160
- Testing
- medication review
- Where
- Denmark
- Volunteers
- 48 people
- Sponsor
- Psychiatric Research Unit, Region Zealand, Denmark
Treatment Resistant Disorders
Deep Brain Stimulation for Treatment-Resistant Schizophrenia
The purpose of this pilot study is to investigate the use of deep brain stimulation (DBS) of the substantia nigra pars reticulata (SNr) in subjects with treatment-resistant schizophrenia.
- Trial name
- NCT07592611
- Testing
- Medtronic Percept with SensSight Deep Brain Stimulation System
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Johns Hopkins University
Treatment Resistant Psychosis, Psychosis
Stratification and Treatment in Early Psychosis Study -ASSIST
The purpose of this trial is: To investigate whether the response to clozapine treatment can be enhanced by adding cannabidiol (CBD), compared to placebo, in treatment resistant psychosis patients.
- Trial name
- STEP-ASSIST (NCT07326124)
- Testing
- CBD 100 mg/mL Oral Solution, Placeb
- Where
- 15 sites in Germany, Greece and 6 more
- Volunteers
- 250 people
- Sponsor
- University of Oxford
Schizophrenia
High Dose Lurasidone for Patients With Treatment Resistant Schizophrenia
The aim of this study is to compare the efficacy of a flexible high dose of lurasidone to a standard dose of lurasidone in patients with treatment resistant schizophrenia or schizoaffective disorder.
- Trial name
- HDL (NCT01569659)
- Testing
- Lurasidone
- Where
- 2 sites in United States
- Volunteers
- 101 people
- Sponsor
- Northwestern University
Schizophrenia Disorders, Schizo Affective Disorder
SEEG-Guided DBS for Schizophrenia
This is a prospective, randomized, interventional study designed to evaluate the efficacy and safety of SEEG-guided deep brain stimulation (DBS) for symptom improvement in patients with treatment-resistant schizophrenia.
- Trial name
- NCT07671261
- Testing
- SEEG implantation, Deep brain stimulation
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Ruijin Hospital